Sulfamylon Cream

Name: Sulfamylon Cream

Clinical pharmacology

SULFAMYLON Cream, applied topically, produces a marked reduction in the bacterial population present in the avascular tissues of second- and third-degree burns. Reduction in bacterial growth after application of SULFAMYLON Cream has also been reported to permit spontaneous healing of deep partial-thickness burns, and thus prevent conversion of burn wounds from partial-thickness to fullthickness. It should be noted, however, that delayed eschar separation has occurred in some cases.

Absorption And Metabolism

Applied topically, SULFAMYLON Cream diffuses through devascularized areas, is absorbed, and rapidly converted to a metabolite (ρ-carboxybenzenesulfonamide) which is cleared through the kidneys. SULFAMYLON is active in the presence of pus and serum, and its activity is not altered by changes in the acidity of the environment.

Antibacterial Activity

SULFAMYLON exerts bacteriostatic action against many gram-negative and gram-positive organisms, including Pseudomonas aeruginosa and certain strains of anaerobes.

What should i discuss with my health care provider before receiving mafenide (sulfamylon)?

You should not use this medication if you are allergic to mafenide.

Before using mafenide, tell your doctor if you are allergic to any drugs (especially sulfa drugs), or if you have:

  • kidney disease; or
  • glucose-6-phosphate dehydrogenase (G6PD) deficiency.

If you have any of these conditions, you may need a dose adjustment or special tests to safely use this medication.

FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant.

It is not known whether mafenide passes into breast milk or if it could harm a nursing baby. Do not receive this medication without telling your doctor if you are breast-feeding a baby.

What should i avoid while being treated with mafenide (sulfamylon)?

Follow your doctor's instructions about any restrictions on food, beverages, or activity while you are being treated with mafenide.

Where can i get more information?

Your pharmacist can provide more information about mafenide.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2013 Cerner Multum, Inc. Version: 1.04. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Sulfamylon Cream Description

Sulfamylon Cream is a soft, white, nonstaining, water-miscible, anti-infective cream for topical administration to burn wounds.

Sulfamylon Cream spreads, easily, and can be washed off readily with water. It has a slight acetic odor. Each gram of Sulfamylon Cream contains mafenide acetate equivalent to 85 mg of the base. The cream vehicle consists of cetyl alcohol, steryl alcohol, cetyl esters wax, polyoxyl 40 stearate, polyoxyl 8 stearate, glycerin, and water, with methylparaben, propylparaben, sodium metabisulfite, and edetate disodium as preservatives.

Chemically, mafenide acetate is α-Amino-ρ-toluenesulfonamide monoacetate and has the following structural formula:

Sulfamylon Cream - Clinical Pharmacology

Sulfamylon Cream, applied topically, produces a marked reduction in the bacterial population present in the avascular tissues of second- and third-degree burns. Reduction in bacterial growth after application of Sulfamylon Cream has also been reported to permit spontaneous healing of deep partial-thickness burns, and thus prevent conversion of burn wounds from partial-thickness to full-thickness. It should be noted, however, that delayed eschar separation has occurred in some cases.

Absorption and Metabolism

Applied topically, Sulfamylon Cream diffuses through devascularized areas, is absorbed, and rapidly converted to a metabolite (ρ-carboxybenzenesulfonamide) which is cleared through the kidneys. SULFAMYLON is active in the presence of pus and serum, and its activity is not altered by changes in the acidity of the environment.

Antibacterial Activity

SULFAMYLON exerts bacteriostatic action against many gram-negative and gram-positive organisms, including Pseudomonas aeruginosa and certain strains of anaerobes.

Indications and Usage for Sulfamylon Cream

Sulfamylon Cream is a topical agent indicated for adjunctive therapy of patients with second- and third- degree burns.

How is Sulfamylon Cream Supplied

16 oz. Plastic Jar (453.6 g) - NDC 51079-623-83
4 oz. Tube (113.4 g) - NDC 51079-623-82
2 oz. Tube (56.7 g) - NDC 51079-623-81

Avoid exposure to excessive heat (temperature above 104° F or 40° C).

For External Use Only.

Keep this and all medications out of the reach of children.

Rx only

Mylan Institutional Inc.
Rockford, IL 61103 U.S.A.

REVISED JULY 2013
030.4

PRINCIPAL DISPLAY PANEL - 2 oz.

NDC 51079-623-81

SULFAMYLON®
CREAM (mafenide acetate
cream, USP)

For Topical Use Only

Rx only   2 oz. (56.7 g)

Mylan Institutional Inc.
Rockford, IL 61103 U.S.A

MI:623:81:1C:R6
523.6

Each gram contains mafenide acetate equivalent to 85 mg base in a water-miscible cream
of cetyl alcohol, stearyl alcohol, cetyl esters wax, polyoxyl 40 stearate, polyoxyl 8 stearate,
glycerin, and water, with methylparaben, propylparaben, sodium metabisulfite, and edetate
disodium as preservatives.

For dosage and administration, read accompanying package insert.
Avoid exposure to excessive heat (temperatures above 104°F or 40°C).
For external use only.
Keep this and all medications out of the reach of children.

SULFAMYLON 
mafenide acetate cream
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:51079-623
Route of Administration TOPICAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
MAFENIDE ACETATE (MAFENIDE) MAFENIDE 85 mg  in 1 g
Inactive Ingredients
Ingredient Name Strength
CETYL ALCOHOL  
STEARYL ALCOHOL  
POLYOXYL 40 STEARATE  
PEG-8 STEARATE  
GLYCERIN  
WATER  
METHYLPARABEN  
PROPYLPARABEN  
SODIUM METABISULFITE  
EDETATE DISODIUM  
Product Characteristics
Color WHITE (soft white) Score     
Shape Size
Flavor Imprint Code
Contains     
Packaging
# Item Code Package Description
1 NDC:51079-623-81 1 TUBE in 1 CARTON
1 56.7 g in 1 TUBE
2 NDC:51079-623-82 1 TUBE in 1 CARTON
2 113.4 g in 1 TUBE
3 NDC:51079-623-83 6 JAR in 1 BOX
3 453.6 g in 1 JAR
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA016763 12/08/2006
Labeler - Mylan Institutional Inc. (039615992)
Revised: 07/2013   Mylan Institutional Inc.
(web3)